Last checked at 25 Sep 2014 11:03
- Home
- Share Prices
- AQSE Share Prices
- Euronext
- Stock Screeners
- Share Chat
- FX
- News & RNS
- Events
- Media
- Trading Brokers
- Finance Tools
- Members
Latest Share Chat
Synairgen Share News (SNG)
SNG Share
Price
SNG Share
News
SNG Share
Chat13
SNG Share
Trades18
SNG
Live RNS
SNG Share
Charts
SNG Level 2
Console
SNG Live
Share Price
SNG Broker
Ratings
SNG Directors
Deals
SNG Financial
Diary
SNG
Fundamentals
SNG Short
Positions
SNG
Media
Synairgen Information
Share Price Information for Synairgen (SNG)
Share Price is delayed by 15 minutes
Get Live Data
Share Price:
6.20
Bid:
5.52
Ask:
7.00
Change:
0.08 (1.31%)
Spread:
1.48 (26.812%)
Open:
6.20
High:
6.20
Low:
6.20
Prev. Close:
6.12
Last checked at -
Watchlists are a member only feature
Login to your account
Don't have an account? Click here to register.Small caps: Cove Energy, Synairgen, Wilmington...
Mon, 17th May 2010 13:02
PR specialist Freshwater cut the dividend as profits fell to £32,000 from £106,000 in the six months to end February. Revenues fell to £3.66m from £4.51m."While the economic environment remains challenging, Freshwater is seeing greater stability and growth potential in most of its markets. Alongside this, the measures we have taken to cut costs have restored EBITDA operating margins to double-digit percentages in the second quarter and this is continuing in the third quarter," it said.Star Aim-listed oil explorer Cove Energy posted a loss of $1.65m, up from $546,000, as it funded its so far very successful drilling programme. Going forward, Cove says that following the success at Windjammer, the offshore partners requested the Mozambique authorities to change the drilling commitment to 6 deepwater wells. This request has been granted. Drilling of these 6 deepwater wells will continue in 2010 through to 2011 and will be followed by an appraisal programme. In Tanzania, it is working with its partners to commercialise the full gas production potential of the Mnazi Bay gas fields. Drug developer Synairgen says data from SNG001, its inhaled interferon beta product, in a new model of influenza shows for the first time that it can prevent the spread of infection from cell to cell, even after an influenza infection has taken hold. "This is potentially an important breakthrough in the treatment of flu virus infection rather than its prevention. This represents an exciting new development opportunity for our inhaled interferon beta product that extends beyond the existing opportunities identified for asthma and COPD," chief executive Richard Marsden added.Publisher Wilmington has decided the time is now right to invest in overseas expansion in the banking and finance sector and in deeper content and enhanced technology. It expects to invest up to £2m over the next 12 months and to see returns in the financial year ending June 2012 and beyond. Since February, "the trading performance of the group has been in line with our expectations," it said, with trading still very tough in the legal business.
More News
4 Jul 2014 12:11
Synairgen raises funds to develop AstraZeneca drug
Synairgen has placed 12.2m shares to raise funds for the assessment and preparation of SNG001, the drug recently licensed from AstraZeneca, across five projects that it has identified as the most suitable direction for its development. The drugs company raised around £5.3m before expenses after is
Read more4 Jul 2014 07:21
15 Jun 2014 12:28
Sunday share tips: Whitbread, Petra Diamonds, Empiric Student Property
Whitbread looks like a reliable investment despite the imminent departure of Chairman Anthony Habgood, Matthew Goodman said in the Sunday Times's Inside the City column. The company was a mess when Habgood took over in 2005 but he has sold peripheral businesses to focus on Premier Inn and Costa Coff
Read more12 Jun 2014 16:37
MARKET COMMENT: FTSE 100 Closes Slightly Higher Amid Iraqi Tensions
LONDON (Alliance News) - The FTSE 100 closed fractionally higher Thursday, having spent the day trading within a tight range, with oil and gas exploration and production company BG Group leading the gains as the price of oil climbed amid escalating violence in Iraq.
Read more
12 Jun 2014 10:23
TOP NEWS: Discount Retailer B&M Prices Biggest London IPO Of 2014
LONDON (Alliance News) - The following is a summary of top news stories Thursday.
----------
COMPANIES
----------
The initial public offering of B&M European Value Retail SA, the discount retailer chaired by former TescoRead more
12 Jun 2014 08:25
London open: Mining stocks pull FTSE 100 lower ahead of data
- Profit taking continues as miners fall - Traders await global economic data - Broker downgrades hit blue chips techMARK 2,839.63 -0.04% FTSE 100 6,827.09 -0.17% FTSE 250 16,073.58 -0.09% UK stocks opened flat on Thursday morning as weakness in the mining sector held back any chances of a rebound
Read more12 Jun 2014 07:42
AstraZeneca signs licence deal with Synairgen
British drugs maker AstraZeneca has signed a licence agreement with AIM-listed Synairgen for the development of SNG000l, a treatment for respiratory tract viral infections in patients with severe asthma. Under the deal, FTSE 100-listed Astra will pay Synairgen a $7.25m up-front fee and potential de
Read more12 Jun 2014 07:36
UK MORNING BRIEFING: AstraZeneca Signs Asthma Deal With Synairgen
LONDON (Alliance News) - UK shares have opened flat Thursday, following negative trading in the US and Asia overnight.
AstraZeneca is the third biggest gainer on the FTSE 100. The drugmaker said it has signed a global licence agreement with AIM-listed biotechnology
12 Jun 2014 06:52
AstraZeneca Licences Asthma Exacerbation Treatment From Synairgen
LONDON (Alliance News) - AstraZeneca PLC said Thursday that it had signed a global licence agreement with AIM-listed biotechnology company Synairgen PLC for its SNG001 compound for the treatment of infections that exacerbate asthma. The compound is used to treat respiratory tract infections
Read more20 Mar 2014 12:47
Synairgen Pretax Loss Narrows On Expenses
LONDON (Alliance News) - Synairgen PLC Thursday said its pretax loss narrowed in its full year 2013 as administrative expenses fell during the period. The respiratory drug discovery and development company said its pretax profit narrowed to GBP2.3 million from GBP2.5 million the previous ye
Read more5 Mar 2014 11:31
Synairgen Jumps As It Raises Cash While Progressing Licensing Talks
LONDON (Alliance News) - Synairgen PLC Wednesday said it has raised GBP1.5 million by placing 3.1 million shares at 48 pence each, money it will use for working capital while it progresses current licensing discussions through to a conclusion. In a statement, the respiratory drug discovery
Read more5 Mar 2014 08:31
UK MORNING BRIEFING: Standard Chartered Profits Fall, Cuts Bonus Pool
LONDON (Alliance News) - Shares have opened mostly lower Wednesday with small-caps out-performing large caps, following Tuesday's relief rally from lowered Ukraine tensions.
Standard Chartered has reported lower 2013 profit and a 15% reduction in its bonus pool, whi
5 Dec 2012 11:10
Synairgen reports 'significant progress'
Synairgen, a respiratory drug discovery and development company, has reported 'significant progress' since the end of June. The firm said that discussions with potential licensing partners for its SNG001 product have progressed, the company has engaged with the US government to investigate the pote
Read more